Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2631 - Real-world outcomes and costs in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Antoine Lafuma

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

A. Lafuma1, F. Cotté2, C. Le Tourneau3, C. Emery1, A. Gaudin2, E. Torreton1, J. Gourmelen4, J. Bonastre5

Author affiliations

  • 1 Health Economy, Cemka-Eval, 92340 - Bourg-la-Reine/FR
  • 2 Health Economics And Outcome Research, Bristol-Myers Squibb, 92500 - Rueil-Malmaison/FR
  • 3 Medical Oncology, Institut Curie, 75248 cedex5 - Paris/FR
  • 4 Ums 011, Uvsq, INSERM, 94800 - Villejuif/FR
  • 5 Cesp, Gustave Roussy, 94800 - Villejuif/FR
More

Resources

Abstract 2631

Background

Overall survival (OS) of patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) is extremely poor. New therapeutic options emerge but need to establish their economic value. The objective was to describe OS and costs in French R/M SCCHN patients.

Methods

The EGB, a random representative sample (1/97th) of the French national healthcare system claims database was used. All adult patients with a diagnosis of SCCHN with a first R/M between Jan 2009 and Dec 2014 were selected. Data were analyzed from the index date (first chemotherapy) until patients’ death or Dec 2015 (minimum follow-up of 12 months). Two periods were distinguished: ‘chemotherapy treatment’ (CT) and ‘end-of-life’ (EoL) (from last CT to death). OS was estimated using the Kaplan-Meier method. Costs included all hospitalizations for SCCHN, consultations, medical devices, biology and imaging procedures, supportive and palliative care, transportation, patients’ out of pocket expenses and indirect cost (daily allowances for sick leaves and disability pensions).

Results

Among 267 patients identified, 85% were men, 44% had metastases at the index date and mean age was 62.0 years (±9.9). Most common tumor locations were oropharynx (29%), oral cavity (12%), larynx (10%) and hypopharynx (10%) but 39% of the patient had multiple locations. Median OS was 9.3 months in overall population with no significant difference between recurrent or metastatic patients (10.5 vs. 8.3 months, p = 0.092). The median OS ranged from 8.3 months for tumors located in the oro/hypopharynx to 10.9 months for those in the oral cavity. The average cost per patient was €48,069 breakdown into €31,136 [95CI: 27,935–34,336] for hospitalizations and €16,933 [14,866–19,000] for outpatient care. During CT period (209 days on average), main cost drivers were CT acquisition and administration (€13,755), home care (€2454), transportation (€1954) and physician fees (€1214). During EoL period (125 days), palliative care (€3548), home care (€977), nursing care (€711) and physician fees (€618) were the main cost drivers.

Conclusions

This analysis of real-world data confirms the poor prognosis in patients with R/M SCCHN and provides cost data for future economic evaluations.

Clinical trial identification

Legal entity responsible for the study

Bristol-Myers Squibb.

Funding

Bristol-Myers Squibb.

Editorial Acknowledgement

Disclosure

A. Lafuma, C. Le Tourneau, C. Emery, E. Torreton, J. Bonastre: Consultancy: BMS. F-E. Cotté, A-F. Gaudin: Employee: BMS. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.